- Home
- LCTX vs TLSA Comparison
LCTX vs TLSA Comparison
Compare LCTX & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- TLSA
- Stock Information
- Founded
- LCTX 1990
- TLSA 2013
- Country
- LCTX United States
- TLSA United Kingdom
- Employees
- LCTX N/A
- TLSA N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- LCTX Health Care
- TLSA Health Care
- Exchange
- LCTX Nasdaq
- TLSA Nasdaq
- Market Cap
- LCTX 95.2M
- TLSA 87.8M
- IPO Year
- LCTX N/A
- TLSA 2000
- Fundamental
- Price
- LCTX $0.49
- TLSA $1.36
- Analyst Decision
- LCTX Strong Buy
- TLSA
- Analyst Count
- LCTX 5
- TLSA 0
- Target Price
- LCTX $4.20
- TLSA N/A
- AVG Volume (30 Days)
- LCTX 1.3M
- TLSA 327.8K
- Earning Date
- LCTX 05-08-2025
- TLSA 05-09-2025
- Dividend Yield
- LCTX N/A
- TLSA N/A
- EPS Growth
- LCTX N/A
- TLSA N/A
- EPS
- LCTX N/A
- TLSA N/A
- Revenue
- LCTX $9,499,000.00
- TLSA N/A
- Revenue This Year
- LCTX N/A
- TLSA N/A
- Revenue Next Year
- LCTX $232.66
- TLSA N/A
- P/E Ratio
- LCTX N/A
- TLSA N/A
- Revenue Growth
- LCTX 6.19
- TLSA N/A
- 52 Week Low
- LCTX $0.37
- TLSA $0.54
- 52 Week High
- LCTX $1.40
- TLSA $1.91
- Technical
- Relative Strength Index (RSI)
- LCTX 54.53
- TLSA 63.09
- Support Level
- LCTX $0.37
- TLSA $0.76
- Resistance Level
- LCTX $0.44
- TLSA $1.53
- Average True Range (ATR)
- LCTX 0.04
- TLSA 0.14
- MACD
- LCTX 0.01
- TLSA 0.06
- Stochastic Oscillator
- LCTX 81.99
- TLSA 78.75
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.